Investing to Protect the United States and the World against Antimicrobial Resistance
Antimicrobial resistance (AR), when germs do not respond to the drugs designed to kill them, threatens to return us to the time when simple infections were often fatal. CDC is committed to protecting people and the future of the healthcare, veterinary, and agriculture industries from the threat of antimicrobial resistance.
The AR Investment Map showcases CDC's critical activities in the U.S. and abroad to combat antimicrobial resistance with investments in laboratory and epidemiological expertise and public health innovation. CDC supports most of these activities through its AR Solutions Initiative, while also leveraging investments from successful programs across the agency for maximum efficiency.
The map also includes projects related to combating antimicrobial resistance that are funded by supplemental appropriations provided to CDC to respond to the COVID-19 pandemic, such as the American Rescue Plan Act or the CARES Act. These activities are also highlighted in a fact sheet.
Go To CDC's Antimicrobial Resistance Website
Select Location
Local health department that received additional funding.
Location of one of CDC's AR Laboratory Network regional labs.
Location of the National Tuberculosis Molecular Surveillance Center.
This data represents CDC's largest funding categories for AR. It shows extramural funding that supports AR activities from multiple funding lines. Some work received full or partial funding from COVID-19 supplemental appropriations, such as the American Rescue Plan Act or the CARES Act. See the FY22 AR Investment Map COVID-19 Fact Sheet for more information.